Hepatitis C

From Citizendium
Revision as of 12:20, 8 July 2011 by imported>Robert Badgett (→‎Treatment: evidence table)
Jump to navigation Jump to search
This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Hepatitis C is "inflammation of the liver in humans caused by hepatitis c virus, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown."[1]

Treatment

Randomized controlled trials of protease inhibitors for hepatitis C genotype 1 infection. [2] [3] [4] [5]
Trial Patients Intervention Comparison Outcome Results
Intervention Control
ADVANCE Study[2]
2011
Previously untreated patients telaprevir peginterferon-ribavirin HCV RNA 24 weeks after last treatment 69% to 75% 44%
REALIZE Study[3]
2011
Previously treated patients telaprevir peginterferon-ribavirin HCV RNA 24 weeks after last treatment 83% to 88% (prior reponse)
54% to 59% (prior partial response)
29% to 33% (prior non-response)
24% (prior reponse)
15% (prior partial response)
5% (prior non-response)
SPRINT-2 study[4]
2011
Previously untreated patients boceprevir peginterferon-ribavirin HCV RNA level 59% to 66% 21%
HCV RESPOND-2 study[5]
2011
Previously treated patients boceprevir peginterferon-ribavirin HCV RNA level 67% to 68% (nonblack patients)
42% to 53% (black patients)
40% (nonblack patients)
23% (black patients)

Two protease inhibitors, telaprevir and boceprevir may add benefit to standard therapy of genotype 1 infection with peginterferon and ribavirin. Telaprevir adds to peginterferon and ribavirin for previously treated[2] and untreated[3] patients. Boceprevir adds to peginterferon and ribavirin for previously treated[5] and untreated[4] patients.

References

  1. Anonymous (2024), Hepatitis C (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. 2.0 2.1 2.2 Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S et al. (2011). "Telaprevir for retreatment of HCV infection.". N Engl J Med 364 (25): 2417-28. DOI:10.1056/NEJMoa1013086. PMID 21696308. Research Blogging.
  3. 3.0 3.1 3.2 Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al. (2011). "Telaprevir for previously untreated chronic hepatitis C virus infection.". N Engl J Med 364 (25): 2405-16. DOI:10.1056/NEJMoa1012912. PMID 21696307. Research Blogging.
  4. 4.0 4.1 4.2 Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS et al. (2011). "Boceprevir for untreated chronic HCV genotype 1 infection.". N Engl J Med 364 (13): 1195-206. DOI:10.1056/NEJMoa1010494. PMID 21449783. Research Blogging.
  5. 5.0 5.1 5.2 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S et al. (2011). "Boceprevir for previously treated chronic HCV genotype 1 infection.". N Engl J Med 364 (13): 1207-17. DOI:10.1056/NEJMoa1009482. PMID 21449784. Research Blogging.